Fusion Pharmaceuticals Inc. (37) | Business Operations (9)

Browse by Subcategory

Recent Contracts

Amendment No. 1 to Collaboration Agreement, dated June 28, 2021, by and between TRIUMF Innovations Inc. and TRIUMF JV and the Company (Filed With SEC on November 9, 2021)
Form of Officer Indemnification Agreement (Filed With SEC on June 22, 2020)
Master Services Agreement, dated as of February 22, 2017, by and between the Centre for Probe Development and Commercialization Inc. and the Registrant (Filed With SEC on June 5, 2020)
Collaboration Agreement, dated December 10, 2020, by and between TRIUMF Innovations Inc. and TRIUMF JV and the Company (Filed With SEC on November 9, 2021)
Amendment No. 2 to Collaboration Agreement, dated July 27, 2021, by and between TRIUMF Innovations Inc. and TRIUMF JV and the Company (Filed With SEC on November 9, 2021)
Amendment No. 3 to Collaboration Agreement, dated August 12, 2021, by and between TRIUMF Innovations Inc. and TRIUMF JV and the Company (Filed With SEC on November 9, 2021)
Strategic Collaboration Agreement by and between Fusion Pharmaceuticals Inc. and AstraZeneca UK Limited, dated October 30, 2020 (Filed With SEC on November 2, 2020)
Form of Director Indemnification Agreement (Filed With SEC on June 22, 2020)
Supply Agreement, dated as of January 17, 2019, by and between the Centre for Probe Development and Commercialization Inc. and the Registrant (Filed With SEC on June 5, 2020)